middl
east
respiratori
syndrom
coronaviru
merscov
highli
pathogen
zoonot
viru
fatal
rate
human
although
sever
vaccin
candid
develop
still
clinic
avail
vaccin
merscov
studi
develop
two
type
merscov
vaccin
recombin
adenoviru
serotyp
encod
merscov
spike
gene
mer
spike
protein
nanoparticl
formul
aluminum
alum
adjuv
next
test
heterolog
primeboost
vaccin
strategi
compar
prime
boost
spike
protein
nanoparticl
vice
versa
homolog
primeboost
vaccin
compris
prime
boost
either
spike
protein
nanoparticl
although
type
vaccin
could
induc
specif
immunoglobulin
g
merscov
neutral
antibodi
merscov
induc
heterolog
primeboost
immun
homolog
immun
spike
protein
nanoparticl
interestingli
cell
activ
induc
immun
schedul
includ
includ
spike
protein
nanoparticl
heterolog
primeboost
vaccin
regimen
includ
elicit
simultan
respons
homolog
primeboost
regimen
thu
heterolog
primeboost
may
induc
longerlast
immun
respons
merscov
appropri
balanc
respons
howev
heterolog
primeboost
homolog
spike
protein
nanoparticl
vaccin
could
provid
protect
merscov
challeng
mice
result
demonstr
heterolog
immun
prime
boost
spike
protein
nanoparticl
could
effici
prophylact
strategi
merscov
infect
middl
east
respiratori
syndrom
coronaviru
merscov
zoonot
beta
coronaviru
infect
sever
kind
anim
includ
human
camel
bat
known
caus
sever
respiratori
symptom
high
mortal
rate
key
receptor
merscov
infect
dipeptidyl
peptidas
wide
distribut
human
endotheli
epitheli
cell
except
case
korea
infect
merscov
occur
kingdom
saudi
arabia
total
number
laboratoryconfirm
case
merscov
infect
death
relat
merscov
infect
sinc
septemb
thu
human
mortal
rate
merscov
infect
approxim
genom
merscov
singlestrand
rna
encod
surfac
glycoprotein
spike
compris
five
nonstructur
protein
orf
main
viral
protein
spike
protein
bind
cell
surfac
receptor
viral
entri
stage
via
receptorbind
domain
rbd
spike
subunit
spike
protein
immunogen
structur
protein
final
goal
current
studi
merscov
vaccin
elicit
neutral
antibodi
specif
merscov
spike
protein
although
sever
approach
develop
merscov
vaccin
report
clinic
approv
vaccin
merscov
previou
studi
investig
viral
vectorbas
vaccin
subunit
vaccin
dna
vaccin
vaccin
use
viral
vector
dna
immun
success
gener
neutral
antibodi
protect
infect
howev
safeti
concern
dna
vaccin
weak
induct
neutral
antibodi
plu
possibl
reduc
efficaci
viral
vector
vaccin
preexist
immun
viral
vector
induc
repeat
immun
ignor
although
protein
subunit
vaccin
induc
neutral
antibodi
usual
elicit
lower
level
cellular
immun
respons
close
associ
rapid
viral
clearanc
infect
occur
addit
subunit
vaccin
could
induc
enough
immun
respons
host
result
failur
make
longterm
memori
antigen
therefor
use
heterolog
primeboost
immun
strategi
combin
recombin
adenoviru
serotyp
deliv
merscov
spike
protein
gene
mer
spike
protein
nanoparticl
type
vaccin
shown
safe
human
trial
result
studi
show
heterolog
primeboost
immun
strategi
induc
good
humor
cellular
immun
respons
includ
neutral
antibodi
activ
cell
merscov
could
protect
mice
merscov
infect
therefor
combin
immun
recombin
spike
protein
nanoparticl
may
avoid
hurdl
preexist
antibodi
induc
repeat
viral
vector
immun
weak
cell
respons
induc
protein
subunit
immun
see
supplement
data
materi
method
detail
regard
cell
viru
prepar
titrat
mer
spike
protein
nanoparticl
sdspage
immunoblot
analysi
recombin
electron
microscopi
enzymelink
immunosorb
assay
elisa
plaqu
reduct
neutral
test
prnt
merscov
infect
statist
analysi
sixweekold
femal
specificpathogenfre
balbc
mice
purchas
dae
han
bio
link
co
ltd
chungcheongbukdo
korea
mous
experi
perform
accord
relev
ethic
guidelin
regul
establish
korean
associ
laboratori
anim
mice
hous
specificpathogenfre
condit
standard
light
cycl
h
lightdark
maintain
accord
protocol
approv
institut
anim
care
use
committe
sungsim
campu
cathol
univers
korea
mice
fed
normal
fat
diet
harlan
laboratori
livermor
ca
usa
steril
water
mice
randomli
alloc
group
six
immun
three
time
indic
tabl
merscov
provid
korean
center
diseas
control
prevent
nation
control
number
experiment
procedur
perform
biosafeti
level
facil
korea
zoonosi
research
institut
chonbuk
nation
univers
viru
passag
titer
vero
cell
spodoptera
frugiperda
insect
cell
obtain
american
type
cultur
collect
maintain
insectxpresstm
medium
merscov
spike
protein
sequenc
refer
ncbi
refer
sequenc
genbank
access
nucleotid
sequenc
codon
optim
optim
express
insect
cell
full
length
spike
gene
clone
baculoviru
transfer
vector
merscov
spike
protein
produc
cell
infect
recombin
baculoviru
spike
protein
purifi
use
combin
anion
exchang
glucos
affin
chromatographi
recombin
adenovirus
encod
mer
spike
protein
human
purchas
sirion
biotech
london
uk
detail
product
protocol
support
inform
si
group
mice
immun
use
heterolog
differ
vaccin
candid
prime
boost
homolog
vaccin
candid
prime
boost
primeboost
immun
detail
immun
schedul
group
shown
tabl
fig
mous
splenocyt
collect
isol
mice
euthan
splenocyt
seed
well
elispot
plate
detect
ifnc
secret
cell
stimul
splenocyt
lgwell
merscov
spikespecif
peptid
ad
cultur
medium
restimul
splenocyt
cultur
day
day
cell
stain
detect
spot
posit
cytokin
analyz
valu
express
mean
standard
deviat
sd
statist
analys
data
perform
use
graphpad
prism
softwar
version
graphpad
softwar
la
jolla
ca
usa
betweengroup
differ
test
use
oneway
analysi
varianc
anova
post
hoc
tukey
honestli
signific
differ
hsd
test
p
consid
statist
signific
adenoviru
serotyp
deliveri
fulllength
mer
spike
protein
gene
produc
test
gene
transduct
effici
cell
line
hela
cell
cell
infect
moi
h
infect
lysat
cell
line
harvest
immunoblot
polyclon
antim
spike
protein
antibodi
produc
rat
immun
mer
spike
protein
nanoparticl
formul
alum
lysat
hela
cell
line
infect
moi
clearli
contain
approxim
mer
spike
protein
fig
data
confirm
cell
express
mer
spike
protein
addit
fulllength
mer
spike
protein
contain
transmembran
domain
amino
acid
produc
insect
cell
cultur
system
fig
confirm
express
western
blot
fig
electron
micrograph
spike
protein
nanoparticl
formul
alum
show
mean
diamet
around
nm
wherea
spike
protein
nanoparticl
formul
alum
around
nm
fig
alumformul
mer
spike
protein
nanoparticl
display
broader
distribut
diamet
formul
alum
immun
mice
three
time
spike
protein
nanoparticl
detail
combin
use
heterolog
homolog
primeboost
immun
indic
tabl
immun
bleed
schedul
shown
fig
sera
immun
mice
collect
pool
week
first
vaccin
prime
analyz
mer
spike
proteinspecif
antibodi
elisa
week
first
immun
week
second
booster
mice
sacrif
week
first
vaccin
spike
proteinspecif
total
igg
could
detect
fig
howev
week
first
vaccin
week
first
booster
spike
proteinspecif
total
igg
increas
group
except
protein
group
final
week
first
vaccin
week
second
booster
vaccin
group
show
induct
mer
spike
proteinspecif
antibodi
wherea
control
pb
group
show
induct
mersspecif
antibodi
fig
spike
protein
nanoparticl
protein
group
show
higher
antibodi
titer
compar
group
spike
group
fig
howev
igg
igg
show
differ
pattern
induct
compar
total
igg
fig
gener
igg
repres
respons
associ
humor
immun
respons
igg
repres
respons
associ
cellular
immun
respons
igg
titer
homolog
primeboost
group
spike
protein
nanoparticl
higher
heterolog
primeboost
group
protein
spike
week
first
vaccin
week
second
booster
fig
igg
protein
group
show
higher
titer
spike
protein
group
howev
spike
group
show
induct
igg
graph
show
mean
optic
densiti
od
standard
deviat
differ
group
assess
oneway
anova
post
hoc
tukey
hsd
test
compar
multipl
treatment
signific
differ
group
indic
letter
group
n
mice
withingroup
sampl
pool
independ
analyz
three
time
week
first
vaccin
week
second
booster
although
show
induct
total
igg
igg
fig
seven
week
first
vaccin
week
second
booster
collect
mous
sera
evalu
presenc
neutral
antibodi
merscov
homolog
spike
protein
nanoparticl
heterolog
protein
immun
group
show
reduct
merscov
serum
group
dilut
fig
although
homolog
heterolog
spike
immun
could
induc
total
igg
mer
spike
protein
fig
group
detect
neutral
antibodi
fig
analyz
mer
spike
proteinspecif
cell
activ
use
elispot
assay
first
stimul
splenocyt
cultur
immun
mice
cellspecif
peptid
kyysiiphsi
mer
spike
protein
interestingli
group
immun
regimen
includ
homolog
group
heterolog
group
includ
protein
spike
show
three
time
higher
level
ifncsecret
cell
homolog
spike
protein
nanoparticl
immun
group
fig
although
homolog
spike
protein
group
show
slight
increas
ifncsecret
cell
compar
pb
group
increas
signific
group
fig
regardless
number
immun
mer
group
includ
immun
clearli
show
induct
ifncsecret
cell
cell
fig
investig
cell
respons
perform
elisa
splenocyt
cultur
supernat
stimul
cellspecif
peptid
measur
level
variou
cytokin
splenocyt
homolog
heterolog
mersspik
proteinor
spike
mice
show
induct
ifnc
tumor
necrosi
factor
tnf
granulocytemacrophag
colonystimul
factor
gmcsf
except
homolog
spike
protein
group
respect
induct
tnfa
fig
data
gener
consist
elispot
analysi
fig
select
two
vaccin
group
test
protect
effect
vaccin
merscov
challeng
homolog
spike
protein
group
heterolog
protein
group
immun
schedul
shown
fig
immun
mice
intranas
infect
pfu
live
merscov
day
inocul
iu
gener
express
merscov
receptor
merscov
infect
control
pb
group
lost
weight
start
weight
howev
vaccin
group
show
significantli
less
weight
loss
start
weight
p
fig
mice
immun
group
sacrif
analyz
ifncsecret
cell
splenocyt
seed
treat
peptid
number
stain
cell
calcul
use
aid
ispot
fluoresc
elispot
reader
system
aid
gmbh
strassberg
germani
mean
optic
densiti
standard
deviat
shown
signific
assess
use
oneway
anova
post
hoc
tukey
hsd
test
compar
multipl
treatment
signific
differ
group
indic
letter
sfu
spotform
unit
group
n
mice
withingroup
sampl
pool
independ
analyz
three
time
fig
induct
cytokin
mersspecif
cell
peptid
treatment
splenocyt
immun
mice
cytokin
level
pgml
cultur
supernat
splenocyt
measur
three
day
merscovspecif
peptid
treatment
supernat
dilut
threefold
analyz
multiplex
cytokin
elisa
mean
optic
densiti
standard
deviat
shown
signific
assess
oneway
anova
post
hoc
tukey
hsd
test
compar
multipl
treatment
signific
differ
group
indic
letter
group
n
mice
withingroup
sampl
pool
independ
analyz
three
time
compar
histopatholog
homologousor
heterologousvaccin
mice
spike
protein
nanoparticl
protein
nonvaccin
control
pb
lung
collect
day
merscov
infect
although
mice
began
regain
weight
day
infect
sever
lesion
lung
clear
pb
group
show
sever
lesion
fig
lung
histolog
section
examin
three
blind
observ
fig
score
point
base
degre
inflammatori
cell
infiltr
observ
hematoxylin
eosinstain
section
fig
spike
protein
protein
group
show
significantli
milder
patholog
merscov
infect
fig
although
first
merscov
outbreak
occur
still
commerci
licens
merscov
vaccin
human
use
therefor
much
research
present
effect
main
target
antigen
spike
protein
previou
studi
report
effect
dna
vaccin
contain
spike
protein
gene
spike
protein
rbd
subunit
vaccin
viral
vector
includ
modifi
vaccinia
viru
ankara
adenoviru
immun
mice
nonhuman
primat
subunit
vaccin
spike
protein
rbd
protein
induc
neutral
antibodi
merscov
indic
induct
humor
immun
respons
dna
vaccin
trigger
activ
cytotox
cell
indic
induct
cellular
immun
respons
howev
subunit
vaccin
usual
induc
weak
cellular
immun
cell
respons
wherea
dna
vaccin
induc
weak
humor
immun
cell
respons
studi
although
induc
spike
proteinspecif
antibodi
antibodi
show
weak
neutral
activ
contrast
induc
mer
spike
proteinspecif
ifncsecret
cell
indic
activ
cell
moreov
level
effector
cytokin
includ
tnfa
gmcsf
ifnc
produc
stimul
cultur
splenocyt
cellspecif
peptid
higher
group
cytokin
associ
immun
respons
therefor
cytokin
elisa
data
indic
immun
trigger
activ
respons
mer
spike
protein
howev
although
vector
advantag
use
develop
vaccin
induct
cellular
immun
respons
easi
product
previou
studi
report
repeat
inject
recombin
reduc
present
target
antigen
antigenpres
cell
presenc
preexist
antibodi
preexist
antibodi
induc
first
prime
vaccin
prevent
immun
respons
could
low
titer
neutral
antibodi
induc
overcom
problem
preexist
antibodi
sever
approach
develop
one
approach
increas
dose
viral
vector
highdos
inject
increas
cytotox
anoth
approach
chang
surfac
antigen
adenoviru
vector
use
booster
immun
rare
serotyp
evad
preexist
antibodi
howev
concern
strategi
difficulti
mass
product
two
type
recombin
virus
although
packag
adenovir
vector
polym
andor
administr
adenoviru
rout
mucos
nasal
inocul
may
circumv
problem
mean
chang
bodi
weight
standard
deviat
shown
asterisk
indic
signific
differ
pb
group
spike
protein
group
p
p
hash
indic
signific
differ
pb
group
protein
group
p
b
histopatholog
examin
homolog
heterolog
vaccin
mice
spike
protein
nanoparticl
protein
nonvaccin
control
pb
lung
collect
day
postinfect
c
hematoxylin
eosinstain
section
lung
examin
score
blind
observ
n
score
absenc
lesion
score
small
occasion
subpleur
foci
score
thicken
intraalveolar
septa
subpleur
fibrot
foci
score
thicken
continu
subpleur
fibrou
foci
intraalveolar
septa
group
n
mice
furthermor
method
depend
experiment
condit
research
skill
therefor
overcom
disadvantag
take
advantag
viral
vector
vaccin
studi
use
heterolog
primeboost
vaccin
strategi
use
first
prime
vaccin
activ
cellular
immun
respons
mer
spike
protein
nanoparticl
use
second
third
first
second
booster
vaccin
activ
humor
immun
respons
shown
fig
strategi
induc
specif
neutral
antibodi
cell
mer
spike
protein
indic
could
effect
trigger
cellular
immun
respons
prime
bypass
limit
viral
vector
boost
mer
spike
protein
nanoparticl
recent
studi
analyz
patient
surviv
mer
viru
infect
demonstr
surviv
depend
induct
cellmedi
immun
respons
neutral
antibodi
analysi
show
correl
sever
symptom
activ
cell
extract
peripher
blood
mononuclear
cell
intens
antibodi
respons
accord
data
patient
stronger
activ
mersspecif
cell
respons
show
faster
viral
clearanc
rel
shorter
exposur
viru
regard
adenoviru
vaccin
known
increas
cellular
immun
respons
via
activ
cell
may
strateg
candid
mer
vaccin
result
shown
fig
indic
protein
group
spike
protein
group
protect
merscov
challeng
indic
smaller
bodi
weight
loss
less
sever
lung
patholog
merscov
infect
howev
spike
protein
group
induc
immun
respons
rather
immun
respons
includ
induct
neutral
antibodi
imbal
respons
suggest
immun
spike
protein
nanoparticl
alon
may
provid
shortterm
protect
viru
infect
longterm
mainten
protect
immun
respons
previous
formalininactiv
respiratori
syncyti
viru
rsv
vaccin
induc
sever
vaccineenhanc
respiratori
diseas
verd
natur
rsv
infect
therefor
safeti
concern
verd
even
long
interv
vaccin
natur
infect
may
increas
merscov
anoth
respiratori
viru
also
shown
induct
allerg
bias
immun
respons
infiltr
inflammatori
cell
airway
lung
main
characterist
verd
rsvinactiv
vaccin
heterolog
primeboost
immun
strategi
spike
protein
nanoparticl
clearli
show
balanc
induct
immun
respons
therefor
vaccin
strategi
may
safe
howev
requir
detail
studi
therefor
heterolog
vaccin
strategi
use
studi
prime
spike
protein
nanoparticl
boost
method
would
feasibl
appli
clinic
effect
use
advantag
viral
vector
vaccin
protein
vaccin
concurr
induc
immun
respons
induc
protect
immun
merscov
